|
Name |
Notoamide H
|
| Molecular Formula | C26H29N3O6 | |
| IUPAC Name* |
(1R,7S,9S,11R,12S)-1',12-dihydroxy-7',7',10,10-tetramethylspiro[3,13-diazatetracyclo[5.5.2.01,9.03,7]tetradecane-11,3'-pyrano[2,3-g]indole]-2,2',14-trione
|
|
| SMILES |
CC1(C=CC2=C(O1)C=CC3=C2N(C(=O)[C@@]34[C@@H]([C@]56[C@H](C4(C)C)C[C@@]7(CCCN7C5=O)C(=O)N6)O)O)C
|
|
| InChI |
InChI=1S/C26H29N3O6/c1-22(2)10-8-13-15(35-22)7-6-14-17(13)29(34)20(32)25(14)18(30)26-16(23(25,3)4)12-24(19(31)27-26)9-5-11-28(24)21(26)33/h6-8,10,16,18,30,34H,5,9,11-12H2,1-4H3,(H,27,31)/t16-,18-,24-,25-,26+/m0/s1
|
|
| InChIKey |
FPTDDDJWQMOTMV-LQKPOZSPSA-N
|
|
| Synonyms |
Notoamide H
|
|
| CAS | NA | |
| PubChem CID | 25180895 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 479.5 | ALogp: | 0.8 |
| HBD: | 3 | HBA: | 6 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 119.0 | Aromatic Rings: | 8 |
| Heavy Atoms: | 35 | QED Weighted: | 0.49 |
| Caco-2 Permeability: | -5.283 | MDCK Permeability: | 0.00002540 |
| Pgp-inhibitor: | 0.976 | Pgp-substrate: | 0.059 |
| Human Intestinal Absorption (HIA): | 0.766 | 20% Bioavailability (F20%): | 0.929 |
| 30% Bioavailability (F30%): | 0.932 |
| Blood-Brain-Barrier Penetration (BBB): | 0.755 | Plasma Protein Binding (PPB): | 68.16% |
| Volume Distribution (VD): | 0.94 | Fu: | 25.40% |
| CYP1A2-inhibitor: | 0.008 | CYP1A2-substrate: | 0.287 |
| CYP2C19-inhibitor: | 0.079 | CYP2C19-substrate: | 0.907 |
| CYP2C9-inhibitor: | 0.596 | CYP2C9-substrate: | 0.164 |
| CYP2D6-inhibitor: | 0.016 | CYP2D6-substrate: | 0.094 |
| CYP3A4-inhibitor: | 0.909 | CYP3A4-substrate: | 0.93 |
| Clearance (CL): | 5.798 | Half-life (T1/2): | 0.276 |
| hERG Blockers: | 0.025 | Human Hepatotoxicity (H-HT): | 0.92 |
| Drug-inuced Liver Injury (DILI): | 0.907 | AMES Toxicity: | 0.529 |
| Rat Oral Acute Toxicity: | 0.978 | Maximum Recommended Daily Dose: | 0.972 |
| Skin Sensitization: | 0.438 | Carcinogencity: | 0.962 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
| Respiratory Toxicity: | 0.823 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002052 | ![]() |
0.792 | D02JNM | ![]() |
0.228 | ||
| ENC004071 | ![]() |
0.693 | D0P0HT | ![]() |
0.226 | ||
| ENC004946 | ![]() |
0.664 | D02QJH | ![]() |
0.221 | ||
| ENC004072 | ![]() |
0.636 | D0W7RJ | ![]() |
0.216 | ||
| ENC002704 | ![]() |
0.621 | D06YFA | ![]() |
0.215 | ||
| ENC002536 | ![]() |
0.621 | D05AFR | ![]() |
0.213 | ||
| ENC002534 | ![]() |
0.621 | D06CWH | ![]() |
0.211 | ||
| ENC004948 | ![]() |
0.621 | D03ZZK | ![]() |
0.210 | ||
| ENC002366 | ![]() |
0.621 | D0IL7L | ![]() |
0.210 | ||
| ENC004945 | ![]() |
0.612 | D03KPZ | ![]() |
0.208 | ||